



## Receipt of R&D Tax Incentive Claim

**Brisbane 22<sup>nd</sup> March 2019:** Further to its announcement dated 4<sup>th</sup> February 2019, Factor Therapeutics (ASX:FTT, the “Company”) advises that it has received \$2.488 million R&D tax rebate for eligible R&D activities undertaken in the financial year ended 31 December 2018.

During 2018, approximately \$5.7 million of eligible R&D expenditure was incurred, primarily in relation to the Phase 2 clinical trial conducted in the United States.

-ENDS-

**Contact for Further Information:**

Dr. Rosalind Wilson

Factor Therapeutics Limited

[r.wilson@factor-therapeutics.com](mailto:r.wilson@factor-therapeutics.com)